Number of urinations per 24 hours (averaged over seven    days)

Number of incontinence episodes per 24 hours (averaged    over seven days)

Volume of urine voided per urination (averaged over two    days)

In three placebo-controlled, I2-week studies with Detrol (2 mg twice daily), patients had a significant reduction (15 - 21 percent) in median number of urinations per 24 hours compared to baseline (baseline median ranged from 10.4 - 11.0 urinations per 24 hours). This reduction was significantly greater than the change for placebo-treated patients.

Data from three placebo-controlled studies showed that patients taking DetroI (2 mg twice daily) decreased their incontinence episodes by 50 to 56 percent from baseline. This reduction was not statistically significant compared with placebo.

The overall number of adverse events with Detrol was comparable to placebo. Reported side effects of Detrol considered treatment-related included dry mouth (39.5 percent Detrol vs. pIacebo 15.9 percent), headache (11.0 percent vs. 7.4 percent), constipation (6.5 percent vs. 4.5 percent), indigestion (5.9 percent vs. 1.7 percent) and dry eyes (3.8 percent vs. 1.7 percent). Discontinuation due to side effects in clinical trials was comparable to placebo (8.0 percent with Detrol vs. 5.7 percent with placebo).

Detrol should not be used in patients with urinary retention, gastric retention and uncontrolled narrow-angle glaucoma.

For more information, ask your healthcare provider at The Woman's Wellness Center, P.C.

 

---

---

Google WWC